Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1344 ARTÍCULOS , VIENDO DEL 76 AL 90

A brief history of APP secretases, their substrates and their functions

Hartmann D.

Curr Alzheimer Res. 2012 Feb;9(2):138-9. doi: 10.2174/156720512799361628.

The role of TMP21 in trafficking and amyloid-β precursor protein (APP) processing in Alzheimer's disease

Bromley-Brits K, Song W.

Curr Alzheimer Res. 2012 May;9(4):411-24. doi: 10.2174/156720512800492521.

α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?

Hernandez CM, Dineley KT.

Curr Drug Targets. 2012 May;13(5):613-22. doi: 10.2174/138945012800398973.

3-(2,4-dimethoxybenzylidene)-anabaseine: a promising candidate drug for Alzheimer's disease?

Zawieja P, Kornprobst JM, Métais P.

Geriatr Gerontol Int. 2012 Jul;12(3):365-71. doi: 10.1111/j.1447-0594.2011.00827.x. Epub 2012 Feb 2.

Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm

Bihaqi SW, Schumacher A, Maloney B, Lahiri DK, Zawia NH.

Curr Alzheimer Res. 2012 Jun;9(5):574-88. doi: 10.2174/156720512800617982.

Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression

Mielke MM, Leoutsakos JM, Corcoran CD, Green RC, Norton MC, Welsh-Bohmer KA, Tschanz JT, Lyketsos CG.

Alzheimers Dement. 2012 May;8(3):180-7. doi: 10.1016/j.jalz.2011.02.011. Epub 2012 Feb 1.

Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient

Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K.

Neurodegener Dis. 2012;10(1-4):138-40. doi: 10.1159/000334537. Epub 2012 Feb 1.

Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain

Lukiw WJ, Alexandrov PN.

Mol Neurobiol. 2012 Aug;46(1):11-9. doi: 10.1007/s12035-012-8234-4.

A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies

Sun N, Funke SA, Willbold D.

Mini Rev Med Chem. 2012 May;12(5):388-98. doi: 10.2174/138955712800493942.

QSAR applications during last decade on inhibitors of acetylcholinesterase in Alzheimer's disease

Wong KY, Duchowicz PR, Mercader AG, Castro EA.

Mini Rev Med Chem. 2012 Sep 1;12(10):936-46. doi: 10.2174/138955712802762365.

Three apoptotic genes are upregulated in a patient with Alzheimer's disease and well-differentiated squamous cell carcinoma

Salemi M, Giuffrida D, Giuffrida MC, Soma PF, La Vignera S, Cimino L, Condorelli RA, Romano C, Bosco P, Vicari LO, Calogero AE.

Int J Biol Markers. 2012 Jan-Mar;27(1):60-3. doi: 10.5301/JBM.2012.8991.

Obesity, insulin resistance, and Alzheimer's disease

Hildreth KL, Van Pelt RE, Schwartz RS.

Obesity (Silver Spring). 2012 Aug;20(8):1549-57. doi: 10.1038/oby.2012.19. Epub 2012 Feb 7.

Dynamics of DNA methylation in aging and Alzheimer's disease

Irier HA, Jin P.

DNA Cell Biol. 2012 Oct;31 Suppl 1(Suppl 1):S42-8. doi: 10.1089/dna.2011.1565. Epub 2012 Feb 7.

The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy

Shiino A, Watanabe T, Shirakashi Y, Kotani E, Yoshimura M, Morikawa S, Inubushi T, Akiguchi I.

J Cereb Blood Flow Metab. 2012 May;32(5):805-15. doi: 10.1038/jcbfm.2012.9. Epub 2012 Feb 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias